Fecal Microbiota Transplantation

As typified by Inflammatory Bowel Disease (IBD), which is the most common intractable disease in Japan with more than 200,000 patients, there are many diseases that are caused by dysbiosis, a disorder of the intestinal microbiota.
We, Metagen Therapeutics, inc. are working on the development and spread of various treatment methods to normalize this dysbiosis, which we call “regeneration of microbiota”.

Fecal Microbiota Transplantation (FMT) is one of the approaches.
FMT attempts to improve disease by replacing the intestinal microbiota by injecting a solution of microbiota obtained by processing the stool of a person with good intestinal microbiota into the intestine of the patient. Many physicians and researchers in Japan and abroad are working day and night to make this a safe and effective treatment method, and it is beginning to be recognized as a standard treatment in leading countries.

Our Chief Medical Officer, Dr. Ishikawa, has been conducting clinical research on FMT at Juntendo University*1, and Metagen Therapeutics, inc. will collect stool used for FMT, and process and distribute it as a bacterial flora solution for social implementation.

*1 Juntendo University: Fecal microbiota transplantation for ulcerative colitis

Microbiome Drug Discovery

Humans have microbiota throughout the body, including in the intestines, skins, and oral cavities. Microbiome research, which analyzes the microbiota, has led to the elucidation of the relationship between the microbiota and health and disease.

Microbiome drug discovery mainly targets the mechanism of action derived from basic research on the intestinal microflora and the intestinal bacteria themselves, and is expected to lead to the development of drugs in the form of conventional small molecules and live bacterial products.

Metagen Therapeutics, inc. is currently developing multiple pipelines and conducting exploratory research for gastrointestinal and immunological diseases by leveraging its FMT platform, Chief Scientific Officer, Dr. Fukuda’s life science research, and Chief Technology Officer, Dr. Yamada’s bioinformatics research.